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Abstract
Background: To assess the efficacy and safety of the herbal medicine, Weng-li-tong (WLT) as monotherapy or
combined with tolterodine in women with overactive bladder (OAB).
Methods: A prospective, randomized, single-blind multi-center trial was performed which included 182 OAB
patients treated with either placebo (n = 26), WLT (n = 52), tolterodine (n = 52) or WLT plus tolterodine (n = 52). The
overactive bladder symptom score (OABSS) and micturition behavior were measured to evaluate treatment efficacy.
Results: In total, 146 patients [placebo (n = 23), WLT (n = 39), tolterodine (n = 41) and WLT plus tolterodine (n = 43)]
completed 8 weeks of treatment. Compared to those treated with placebo, patients in three intervention groups
showed significant improvements in the OABSS, voiding frequency, average voided volume and urgency
incontinence. WLT had a slower onset than tolterodine or combination therapy in reducing urgency incontinence.
Compared with tolterodine, WLT had a weaker effect in improving OABSS (P = 0.022) and daily voiding frequency
(P = 0.034). The combination therapy had better efficacy than WLT or tolterodine alone in improving the OABSS,
voiding frequency and voided volume. No significant differences in the changes in quality of life scores were
observed among the three intervention groups. Residual urine increased significantly in tolterodine group
(P = 0.004), but not in combination group. WLT resulted in fewer adverse effects than tolterodine such as dry
mouth (P = 0.002), weak stream (P = 0.002) and less residual urine (P < 0.001).
Conclusions: WLT could improve OAB symptoms in women, while it had slower onset and weaker efficacy but
fewer adverse effects than tolterodine. The combination of WLT and tolterodine was more efficacious than
tolterodine alone in improving OAB symptoms.
Trial registration: Chinese Clinical Trial Registry [ChiCTR-IPR-14005626]. Date of registration: 7 December 2014.
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Background
Overactive bladder (OAB) is defined as a syndrome in-
volving urinary urgency, usually accompanied by urinary
frequency and nocturia, with or without urgency incon-
tinence, in the absence of urinary tract infection or other
obvious pathology [1].
Although behavioral modifications and pelvic floor
physiotherapy are first-line options, pharmacologic ther-
apy such as anticholinergic drugs is the mainstay of
OAB treatment [2]. As OAB is a chronic disease requir-
ing long-term treatment, adherence and compliance to
drug usage is of great importance. Unfulfilled treatment
expectation and poor adherence to anticholinergic medi-
cations remain a major challenge in the treatment of
OAB [3] and lead to the use of over-the-counter alterna-
tive substances [4], of which herbal medication is one of
the most preferred treatment alternatives or adjuvants to
anticholinergic medications.
Weng-Li-Tong capsule (WLT, North China Pharma-
ceutical Group Corporation, Hebei, China; Sino-FDA
Registration No. z19991104), a traditional Chinese
medicine, is a mixture of herbal medicines, including
Semen Coicis and Bulbus Fritillariae Thunbergii. In
clinical practice, WLT can ameliorate the symptoms of
urinary urgency and urinary frequency, and has anti-
inflammatory effects in chronic prostatitis [5]. We
designed the present clinical trial to determine if WLT
could provide similar efficacy in women with OAB as
an effective adjunctive therapy to anticholinergic me-
dications. As tolterodine is a representative anticho-




This study was a randomized, single-blind (to patients)
placebo-controlled, prospective multi-center trial, and
was conducted at the Department of Urology of Shanghai
Ninth People’s Hospital, Ruijin Hospital and Renji Hos-
pital. Patient screening was started in January 2014. All
participants were divided into the following four treat-
ment groups: placebo (with same appearance of WLT),
WLT alone, tolterodine alone and WLT combined with
tolterodine at the ratio of 1:2:2:2 from December 2014
to June 2015 after the trial was finally approved by the
ethics committee. The sample size was constructed to
include 21 cases in the placebo group and 40 patients
in each of the three intervention groups, aiming to de-
tect a between-group difference in overactive bladder
symptom score (OABSS) change of at least 10 % at
8 weeks with a two-sided significance level of 0.05 and
a power of 0.9 (using the calculate tool website: http://
powerandsamplesize.com/Calculators) (Fig. 1). The flow
chart of this trial is shown in Fig. 1.
The trial was approved by the ethics committee of
Shanghai Ninth People’s Hospital (Number: 201497)
and registered at the Chinese Clinical Trial Registry
(ChiCTR-IPR-14005626,http://www.chictr.org.cn/) and
can be searched at WHO ICTRP Search Portal (http://
apps.who.int/trialsearch/) using the registry number.
Written informed consent was provided by each partici-
pant. In addition to the Handbook for Good Clinical Re-
search Practice (GCRP) and the International Conference
on Harmonization, this trial was also conducted in ac-
cordance with Shanghai local regulatory requirements and
laws. Reporting of this trial was in accordance with the
CONSORT 2010 checklist and CONSORT extension for
herbal medicine interventions.
The primary outcome was reduction in the OABSS,
and the secondary outcomes included a decrease in
urgency incontinence and urinary frequency with im-
provement in quality of life.
Inclusion criteria
The inclusion criteria for participants during the screen-
ing period were as follows: (1) female, aged from 18 to
75 years; (2) urinary urgency and urinary frequency, with
or without urge incontinence; (3) average voiding vol-
ume < 200 ml; (4) urinalysis excluded urinary tract infec-
tion and represented no sign of urinary tract infection
4 weeks before screening; (5) patients were able to
complete a micturition diary with good compliance and
no previous anticholinergic usage. Exclusion criteria in-
cluded: (1) severe cardiac diseases and arrhythmia; (2)
severe hepatic and renal diseases, in which case as-
partate aminotransferase, alanine aminotransferase and
creatinine were 1.5 times greater than the upper limit of
the normal reference range; (3) contraindications to
anticholinergic therapy, such as urinary retention, gastric
retention, uncontrolled angle-closure glaucoma or allergy
to WLT; (4) acute urinary tract infection with symptoms
during the screening period; (5) hematuria of unknown
cause, cancer, interstitial cystitis, neurogenic bladder,
bladder outlet obstruction, urethral catheterization, brain
trauma, thyroid diseases, diabetes mellitus and other
diseases which the researchers recognized as unsuitable
for inclusion in this trial; (6) pregnancy, or preparation
for pregnancy.
Interventions
In total, 182 participants were recruited and 146 patients
underwent five visits over 8 weeks, which included base-
line screening at week 0 (visit 1), randomization, allocation
and start of drug intake 3 days after baseline screening
(visit 2) with follow up at week 2 (visit 3), week 4 (visit 4)
and week 8 (visit 5) (Fig. 1).
The tolterodine group received extended-release tol-
terodine (4 mg per day, GSK, Nanjing, China), and the
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WLT group was treated with WLT (400 mg per capsule,
three capsules twice daily). The combination group
received WLT plus tolterodine at the same doses as
described above.
Components of the Weng-Li-Tong (WLT) capsule
One WLT capsule (400 mg) contains Ma-yuen Job-
stears Seed (Semen Coicis, 66.3 mg), Chekiang Fritil-
lary Bulb (Bulbus Fritillariae Thunbergii, 44.2 mg),
Armand Clematis Stem (Caulis Clematidis Armandii,
39.8 mg), Cape Jasmine (Gardenia jasminoides Ellis,
39.8 mg), Japanese Honeysuckle Flower Bud (Flos
Lonicerae, 44.2 mg), Japanese Inula Flower (Flos Inulae
Japonicae, 39.8 mg), Hirsute Bugleweed Herb (Herba
Lycopi Hirti, 39.8 mg), Verdigris (Mineralium Viridia-
num, 2.2 mg) and Liquorice Root (Radix Glycyrrhizae,
17.7 mg) with Radix Astragali (53 mg) and Radix Offi-
cinale (13.2 mg).
Measurements
The patients’ perception of the impact of symptoms on
their physical and emotional well-being is a major out-
come parameter of OAB treatment. Measurement of
patient-reported outcomes was aided by the OABSS [6],
which included the frequency of micturition per day and
per night, urinary urgency and urge incontinence. To
determine bladder symptoms more precisely, a volume
chart over three consecutive days was used in this re-
search, and included data on micturition frequency (also
included in OABSS), voided volume per micturition and
episodes of urinary incontinence.
In addition to baseline clinical data, complete blood
cell count, urinalysis, liver and renal panels, blood glu-
cose and ultrasonography for residual urine were carried
out at visit 1 and visit 5. The OABSS and the voiding
volume chart were collected at start, 4 weeks and
8 weeks of treatment. Quality of life (QOL) scores were
Fig. 1 Protocol of patient enrolment and follow-up progress through this trial
Xiao et al. BMC Urology  (2016) 16:49 Page 3 of 7
recorded at the begining and after 8 weeks of treatment
using the scale of 0 (very well) to 5 (very bad) as a
secondary endpoint.
Safety assessments
Adverse events (AEs) were evaluated from 2 weeks to
8 weeks of treatment. The severity of each AE was deter-
mined by the Clavien grading system. A severe AE was
considered unbearable and required withdrawal of the
drug or medical intervention.
Statistical analysis
All statistical analyses were performed using SPSS
Statistics version 20.0 (SPSS Inc., Chicago, IL, USA). P-
values were two-sided and considered statistically sig-
nificant if less than 0.05. Baseline data in four groups
were compared using the independent sample t-test for
patients who completed the trial. After treatment,-
reductions in the OABSS, voids per 24 h and urinary
incontinence with the changes in voided volume or
residual urine were compared by ANOVA using the
pairwise LSD test. The incidence of AEs was analyzed
using the nonparametric Kruskal–Wallis test. Are these
edits OK?
Results
A total of 260 patients diagnosed with OAB were
screened for eligibility. Of these, 182 patients who
met the inclusion criteria were randomized and al-
located into four groups with 26 patients in the
placebo group and 52 patients in each of the three
intervention groups. In total, 146 patients finished
the treatment and follow-up periods: 23 in the pla-
cebo group, 39 in the WLT group, 41 in the tol-
terodine group and 43 in the combination group
(Fig. 1). No significant differences in baseline demo-
graphic and clinical data, such as age, 24-h voiding
frequency, average voided volume, urinary incontinence
per 24 h and residual urine were observed between the
groups (Table 1).
Efficacy
The patients in all three intervention groups showed
significant improvement in the OABSS, frequency, aver-
age voided volume and urge incontinence after 8 weeks
of treatment (Table 2).
Combination therapy showed better efficacy than the
other two intervention groups in terms of improvement
in the OABSS, frequency and voided volume, while the
reduction in urgency incontinence in the combination
group was greater than that in the WLT group, but simi-
lar to that in the tolterodine group. Interestingly, the
increase of residual urine was only significant in toltero-
dine group, but not in WLT or combination group
(Table 3). An improvement in QOL is defined as a de-
crease in the QOL score of one or more. The number of
intent-to-treat patients in the three intervention groups
who improved at week 8 was 30 (57.9 %), 32 (61.5 %)
and 40 (76.9 %), respectively, with no significant
differences. However, the percentage of patients who
improved in the intervention groups was much higher
than that in the placebo group (3; 11.5 %) (all P <0.001)
(Table 3).
Comparison between WLT and tolterodine showed
that WLT had weaker efficacy than tolterodine in re-
ducing the OABSS (P = 0.022) and voiding frequency
per 24 h (P = 0.034). The percentage of patients with
urgency incontinence decreased significantly in tolter-
odine or combination group, but marginally in WLT
group (P = 0.051). WLT did not improve the episode
of urgency incontinence at week 4 due to its slower
onset, whereas it had a similar effect as tolterodine at
week 8 (P = 0.113) (Table 3).
Safety
The incidence of AEs in combination group and toltero-
dine group was similar, while AEs in WLT group were
significantly fewer than those in tolterodine group which
included dry mouth (P = 0.002), weak stream (P = 0.002)
and less residual urine (P < 0.001). WLT resulted in a
slightly higher incidence of diarrhea (12.8 %, P = 0.024)
than tolterodine but was tolerable. No renal or hepatic
malfunction or severe AEs were observed (Table 4).
Table 1 Basic demographics and baseline clinical data
Group(n) Placebo (26) WLT (52) Tolterodine (52) Combination (52) P-value
Age (y) 47(27–72) 49 (25–71) 48 (26–73) 48 (28–75) 0.832
OABSS 9.2 ± 2.6 8.9 ± 2.2 9.1 ± 2.8 9.6 ± 2.5 0.252
Voids/24 h 13.5 ± 2.9 13.0 ± 2.1 13.2 ± 2.8 13.8 ± 2.3 0.096
VV (ml) 140 ± 35 143 ± 22 141 ± 36 142 ± 31 0.887
Patients with UI 20 42 40 43 0.874
UI/24 h 1.10 ± 0.98 1.06 ± 0.96 0.97 ± 0.96 1.13 ± 1.05 0.783
RU (ml) 6.8 ± 9.7 5.6 ± 8.8 7.1 ± 9.8 6.2 ± 9.1 0.759
WLT weng-li-tong, OABSS overactive bladder symptom score, VV void volume, UI urinary incontinence, RU residual urine, QOL quality of life
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Discussion
This is the first randomized clinical trial to investigate the
efficacy and potential applicability of WLT as an adjunct-
ive therapy to anticholinergic medication in the treatment
of OAB in women. WLT improved OAB symptoms with
better safety than tolterodine and showed a synergistic
effect between WLT and tolterodine. The underlying
pharmacological mechanism of WLT in the treatment of
OAB should be investigated in the future, as this may indi-
cate its mode of action.
According to a previous randomized, double-blind
placebo-controlled trial, WLT was reported to have fa-
vorable therapeutic outcomes in patients with chronic
prostatitis with acceptable side effects [7]. Originally
targeting at benign prostate hyperplasia or prostatitis,
WLT was reported to have analgesic and microcirculation-
Table 2 Efficacy comparison within groups between baseline, visit 4 (4 weeks) or visit 5 (8 weeks)
Placeboa WLT P-value Tolterodine P-value Combination P-value
OABSS
baseline 9.2 ± 2.6 8.9 ± 2.2 9.1 ± 2.8 9.6 ± 2.5
visit 4 9.0 ± 2.8 8.0 ± 2.5 <0.001 8.0 ± 2.6 <0.001 7.4 ± 2.3 <0.001
visit 5 9.4 ± 2.7 8.2 ± 1.8 0.009 7.5 ± 2.7 <0.001 5.7 ± 2.0 <0.001
Voids/24 h
baseline 13.5 ± 2.9 13.0 ± 2.1 13.2 ± 2.8 13.8 ± 2.3
visit 4 13.2 ± 3.1 11.4 ± 2.0 <0.001 11.7 ± 2.6 <0.001 11.7 ± 2.3 <0.001
visit 5 13.3 ± 3.2 12.0 ± 2.3 0.012 11.0 ± 2.6 <0.001 10.0 ± 2.5 <0.001
VV (ml)
baseline 140 ± 35 143 ± 22 141 ± 36 132 ± 42
visit 4 135 ± 37 159 ± 33 <0.001 154 ± 38 <0.001 162 ± 35 <0.001
visit 5 136 ± 38 152 ± 24 0.025 167 ± 40 <0.001 192 ± 59 <0.001
Patients with UI
baseline 18/23 31/39 32/41 35/43
visit 4 16/23 29/39 0.788 24/41 0.096 27/43 0.091
visit 5 17/23 22/39 0.051 21/41 0.02 23/43 0.011
UI/24 h
baseline 1.10 ± 0.98 1.06 ± 0.96 0.97 ± 0.96 1.13 ± 1.05
visit 4 1.20 ± 1.08 1.04 ± 0.90 0.811 0.55 ± 0.70 <0.001 0.55 ± 0.60 <0.001
visit 5 1.18 ± 1.10 0.70 ± 0.65 <0.001 0.36 ± 0.51 <0.001 0.33 ± 0.40 <0.001
RU (ml)
baseline 6.8 ± 9.7 5.6 ± 8.8 7.1 ± 9.8 6.2 ± 9.1
visit 5 7.2 ± 10.2 4.9 ± 7.9 0.412 18.3 ± 29.7 0.004 6.4 ± 9.3 0.822
WLT weng-li-tong, OABSS overactive bladder symptom score, VV void volume, UI urinary incontinence, RU residual urine
aPlacebo group showed no difference (all P > 0.05) of all parameters between baseline and visit 4/5
Table 3 Efficacy comparison within groups at visit 5 (8 weeks)
Group (n) Placeboa (23) WLT (39) Tolterodine (41) Combination (43) P-value
Wvs T W vs C T vs C
OABSS 0.22 ± 0.83 −0.72 ± 1.71 −1.54 ± 1.07 −3.9 ± 1.8 0.022 <0.001 <0.001
Voids/24 h - 0.21 ± 0.77 −0.97 ± 2.3 −2.2 ± 1.6 −3.9 ± 2.1 0.034 <0.001 <0.001
VV (ml) −4.8 ± 15.1 10.9 ± 24.4 24.6 ± 21.6 49.6 ± 43.9 0.135 <0.001 0.001
UI/24 h 0.02 ± 0.45 −0.36 ± 0.58 −0.61 ± 0.63 −0.78 ± 0.85 0.113 0.008 0.281
RU (ml) 0.5 ± 2.8 −0.9 ± 3.9 11.5 ± 23.2 0.2 ± 3.8 <0.001 0.109 <0.001
QOL improvement in ITT patients 11.5 % 57.9 % 61.5 % 76.9 % 0.842 0.059 0.136
WLT weng-li-tong, OABSS overactive bladder symptom score, VV void volume, UI urinary incontinence, RU residual urine, QOL quality of life, ITT intent-to-treat, W
weng-li-tong, T tolterodine, C combination
aThe changes of OABSS, voids/24 h, VV and UI with improve rate in placebo group were all significantly less than other 3 groups (all P < 0.001), except RU change
was similar to WLT (P = 0.131) or combination group (P = 0.312)
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improving actions, and an anti-inflammatory effect in
mouse models [8]. As aberrant neurogenic activity [9],
cerebral alterations [10] and atypical or latent bladder in-
fections [11] are involved in the pathogenesis of OAB,
these factors may be controlled by WLT’s analgesic and
anti-inflammatory effects. WLT could also block alpha1-
receptor mediated vasoconstriction [12], thus reducing re-
sidual urine in combination with tolterodine.
The components of WLT may provide some insight into
its pharmacological mechanism against OAB. Mineralium
Viridianum was reported to have an important anti-
inflammatory function [13] while Semen Coicis has an
analgesic effect [14]. Peimine, extracted from Bulbus Fritil-
lariae Thunbergii, inhibits the production of inflammatory
cytokines induced by lipopolysaccharide (LPS) by blocking
mitogen activated protein kinases (MAPKs) and NF-kB
signaling pathways [15]. Caulis Clematidis Armandii has
anti-neuroinflammatory activities [16]. Geniposide, ex-
tracted from Gardenia jasminoides Ellis, markedly inhib-
ited LPS-induced TNF-α, IL-6 and IL-1β production both
in vitro and in vivo [17]. Flos Lonicerae extracts exhibit
antioxidant activity [18]. The anti-inflammatory activities
of Flos Inulae Japonicae may be attributed to the inhib-
ition of NO, iNOS and cytokine expression through the
down-regulation of NF-kB activation via suppression of
IkBα and MAPK phosphorylation in macrophages [19].
Luteolin-7-O-beta-D-glucuronide methyl ester was isolated
and identified as the major compound in the ethyl acetate
fraction of Herba Lycopi Hirti and had antioxidant activities
[20]. The anti-inflammatory effect of Radix Glycyrrhizae is
partially achieved by regulating the ERK signal pathway and
inhibiting iNOS and COX-2 gene and protein expression
through extracellular signals of MAPKs [21].
Some herbal medicines have been reported to have
potential therapeutic effects in the treatment of OAB or
lower urinary symptoms [22, 23]. However, there are few
clinical trials of traditional Chinese medicines in the
treatment of OAB. Our data indicated that WLT markedly
reduced OABSS as the primary endpoint. For secondary
endpoints of this trial, it could also decrease urinary
frequency or urgency incontinence with voiding volume
increase. Moreover, WLT improved QOL in 57.9 % of
intent-to-treat patients. Despite its slower onset and
weaker efficacy compared to tolterodine, WLT had fewer
side effects. A synergistic effect between WLT and tol-
terodine could enhance the benefit of antimuscarinics
in long-term therapy and prevent an increase in re-
sidual urine. WLT could probably be an alternative
agent in OAB women who are unsuitable for anti-
cholinergic drugs.
The limitations of this study include the small number
of patients and short duration of treatment. A large
prospective double-blind randomized placebo-controlled
study is needed to confirm the efficacy of WLT in the
clinical management of OAB.
Conclusions
WLT could improve OAB symptoms in women, while it
had slower and weaker efficacy but fewer adverse effects
than tolterodine. The combination of WLT and toltero-
dine was more efficacious than tolterodine alone in im-
proving OAB symptoms, indicating possible synergy
between WLT and anticholinergic agents.
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